Legal & General Group Plc reduced its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 2.6% during the first quarter, Holdings Channel reports. The institutional investor owned 4,054 shares of the biopharmaceutical company’s stock after selling 107 shares during the period. Legal & General Group Plc’s holdings in Esperion Therapeutics were worth $142,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in ESPR. Quantbot Technologies LP purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $158,000. C WorldWide Group Holding A S purchased a new position in Esperion Therapeutics during the first quarter worth about $162,000. Princeton Alpha Management LP purchased a new position in Esperion Therapeutics during the first quarter worth about $205,000. Bank of Montreal Can boosted its position in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the period. Finally, American International Group Inc. boosted its position in Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares during the period. Institutional investors and hedge funds own 85.39% of the company’s stock.

Esperion Therapeutics, Inc. (NASDAQ ESPR) traded up 0.56% during trading on Wednesday, hitting $48.88. 79,506 shares of the stock were exchanged. Esperion Therapeutics, Inc. has a 52 week low of $9.40 and a 52 week high of $57.38. The firm’s market cap is $1.10 billion. The firm’s 50-day moving average is $47.37 and its 200 day moving average is $36.14.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period in the prior year, the company earned ($0.62) EPS. Analysts expect that Esperion Therapeutics, Inc. will post ($7.30) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Esperion Therapeutics, Inc. (ESPR) Position Lowered by Legal & General Group Plc” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/16/esperion-therapeutics-inc-espr-position-lowered-by-legal-general-group-plc.html.

A number of equities analysts have issued reports on ESPR shares. Jefferies Group LLC started coverage on Esperion Therapeutics in a report on Monday, July 10th. They set a “hold” rating and a $55.00 target price for the company. Stifel Nicolaus reiterated a “buy” rating and set a $60.00 target price (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. UBS AG reiterated a “buy” rating and set a $57.00 target price (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Citigroup Inc. reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $42.51.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.